Arcadia Biosciences, Inc.
RKDA
$3.15
$0.155.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.81% | 20.65% | 9.60% | 0.79% | -9.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.81% | 20.65% | 9.60% | 0.79% | -9.81% |
| Cost of Revenue | 65.22% | 52.96% | 11.21% | -23.04% | -42.07% |
| Gross Profit | -10.36% | -6.98% | 7.56% | 40.47% | 66.88% |
| SG&A Expenses | 5.43% | 21.07% | -0.67% | -25.41% | -40.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.90% | 27.64% | 1.81% | -24.93% | -40.79% |
| Operating Income | -11.80% | -33.35% | 2.87% | 36.77% | 52.78% |
| Income Before Tax | -3,806.08% | -167.73% | 39.59% | 92.65% | 98.43% |
| Income Tax Expenses | 14.29% | 0.00% | 0.00% | -50.00% | -53.33% |
| Earnings from Continuing Operations | -3,664.89% | -168.93% | 39.54% | 92.59% | 98.37% |
| Earnings from Discontinued Operations | 93.07% | 84.70% | 60.25% | 8.90% | -54.97% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -100.00% |
| Net Income | -11.10% | 71.28% | 49.66% | 62.09% | 56.73% |
| EBIT | -11.80% | -33.35% | 2.87% | 36.77% | 52.78% |
| EBITDA | -15.42% | -38.89% | 0.62% | 36.30% | 53.48% |
| EPS Basic | -10.71% | 71.33% | 63.75% | 76.80% | 76.51% |
| Normalized Basic EPS | -147.65% | -544.28% | 33.50% | 70.74% | 80.09% |
| EPS Diluted | -1.60% | 62.69% | 60.60% | 74.37% | 74.40% |
| Normalized Diluted EPS | -164.92% | -458.40% | 43.57% | 78.84% | 86.37% |
| Average Basic Shares Outstanding | 0.30% | 0.30% | 10.30% | 28.05% | 55.13% |
| Average Diluted Shares Outstanding | -7.79% | 33.67% | 47.02% | 70.71% | 106.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |